Soluble TWEAK plasma levels as a novel biomarker of endothelial function in patients with chronic kidney disease.

@article{Ylmaz2009SolubleTP,
  title={Soluble TWEAK plasma levels as a novel biomarker of endothelial function in patients with chronic kidney disease.},
  author={M. Yılmaz and J. Carrero and A. Ortiz and J. Mart{\'i}n-Ventura and A. Sonmez and M. Sağlam and H. Yaman and M. Yenicesu and J. Egido and L. Blanco-Colio},
  journal={Clinical journal of the American Society of Nephrology : CJASN},
  year={2009},
  volume={4 11},
  pages={
          1716-23
        }
}
BACKGROUND AND OBJECTIVES Recently, we showed that soluble TNF-like weak inducer of apoptosis (sTWEAK) plasma levels are diminished in hemodialysis patients and had additive effects with IL-6 on survival. Because sTWEAK plasma level has been associated with the presence of chronic kidney disease (CKD) and cardiovascular disease, we hypothesized that in patients with CKD, sTWEAK levels may relate to the increased prevalence of endothelial dysfunction that usually accompanies the decline of… Expand
Soluble TWEAK and Major Adverse Cardiovascular Events in Patients with CKD.
Soluble TWEAK and PTX3 in nondialysis CKD patients: impact on endothelial dysfunction and cardiovascular outcomes.
Soluble TWEAK independently predicts atherosclerosis in renal transplant patients
Lower plasma soluble TWEAK concentration in patients with newly diagnosed hypertension.
...
1
2
3
4
5
...

References

SHOWING 1-10 OF 44 REFERENCES
Additive effects of soluble TWEAK and inflammation on mortality in hemodialysis patients.
Changes in fat mass correlate with changes in soluble sCD163, a marker of mature macrophages, in patients with CKD.
Inflammation and Atherosclerosis
...
1
2
3
4
5
...